Login to Your Account

JPM 2015

Hospira: Biosimilars see slower market uptake, fewer players vs. generics

By Jennifer Boggs
Managing Editor

Wednesday, January 14, 2015

SAN FRANCISCO – Opening his presentation during the J.P. Morgan Healthcare Conference Wednesday morning, Hospira Inc. CEO Michael Ball zipped through updates on the firm's injectable and device businesses and focused the majority of his talk on the firm's efforts in biosimilars.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription